The follow-up to the national adoption of the abandonment standard: the replacement company has been determined!

The domestic pharmaceutical giant North China Pharmaceutical Co.
, Ltd.
abandoned the bid and was disqualified from participating in the national procurement within 9 months by the United Procurement Office
.

In the past two days, some friends have left messages to ask about the follow-up replacement manufacturers, here to share with you
.

According to the Shandong Provincial Public Resources Trading Center, according to the “Letter on Effectively Supplying the Third Batch of National Centralized Drugs Ibuprofen Sustained- -1) According to relevant regulations, Zhuhai Rundu Pharmaceutical Co.
, Ltd.
is a substitute company for ibuprofen sustained-release capsules in Shandong Province after the selection process of replacement companies
.

The replacement company is currently in the publicity period, as of August 25
.

Therefore, the current drug supply problem in medical institutions has been resolved
.

Event review

On August 20, the National Organization for Pharmaceutical Joint Procurement Office issued the "Announcement on Including North China Pharmaceutical Co.
, Ltd.
on the Violation List".
The announcement showed that because North China Pharmaceutical failed to supply drugs in accordance with the agreed procurement volume, the joint procurement member units collectively After deliberation, it was decided to include it on the "list of violations" and cancel the company's qualification to participate in the centralized drug procurement activities organized by the state from August 11, 2021 to May 10, 2022
.

The North China pharmaceutical industry is called "Hua Yao".
Its predecessor, North China Pharmaceutical Factory, was a key construction project during China's "First Five-Year Plan" period.
Preparations began as early as June 1953, and it was completed and put into production in June 1958, creating China's large-scale production of antibiotics.
The history of China is the earliest “big pharmaceutical factory” in China.
North China Pharmaceutical has made important contributions to the domestic shortage of medicines and medicines at that time, and has witnessed the decades of development of China’s national pharmaceutical industry.

In 1992, North China Pharmaceutical Factory was reorganized to establish North China Pharmaceutical Co.
, Ltd.
, and listed on the Shanghai Stock Exchange in 1994.
Its main products involve nearly a thousand products in the fields of chemical pharmaceuticals, modern biotechnology drugs, vitamins and nutraceuticals, modern Chinese medicines, and biological agricultural and veterinary medicines.
Regulations, the annual operating income exceeds 10 billion
.

The original text is as follows:

Announcement on Including North China Pharmaceutical Co.
, Ltd.
on the Violation List

North China Pharmaceutical Co.
, Ltd.
, the selected company in the third batch of countries to organize centralized drug purchases of ibuprofen sustained-release capsules, failed to supply the agreed purchase volume in Shandong Province according to the agreement.
After many talks and consultations with relevant departments, the supply situation has not improved
.

According to the third batch of national centralized procurement "National Drug Centralized Procurement Document (GY-YD2020-1)", after the collective deliberation of the member units of the Joint Drug Procurement Office of the State Organization, it was decided to include North China Pharmaceutical Co.

Hereby announce

National Organization Drug Joint Procurement Office

August 20, 2021